Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study

Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment

(2021) Thorsteinn Loftsson et al.   ACTA OPHTHALMOLOGICA

Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes

(2020) Thomas A Ciulla et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis

(2019) Ba' Pham et al.   BMJ Open

Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab

(2019) Neil M. Bressler et al.   JAMA Ophthalmology

Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia

(2019) Kimberly L Spooner et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice

(2018) Nancy M. Holekamp et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits

(2018) Sunna Johannsdottir et al.   JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

Topical drug delivery to the posterior segment of the eye: The effect of benzalkonium chloride on topical dexamethasone penetration into the eye in vivo

(2018) Sunna Johannsdottir et al.   JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye

(2017) Thorsteinn Loftsson et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Pharmacokinetic aspects of retinal drug delivery

(2017) Eva M. del Amo et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Systemic Safety of Prolonged Monthly Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

(2016) Robert L. Avery et al.   JAMA Ophthalmology

Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

(2016) John A. Wells et al.   JAMA Ophthalmology

Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis - a pilot study

(2015) Shiri Shulman et al.   ACTA OPHTHALMOLOGICA

Topical dexamethasoneγ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema

(2015) Akihiro Ohira et al.   ACTA OPHTHALMOLOGICA

A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study)

(2015) J Ramu et al.   EYE

Topical dexamethasone-cyclodextrin microparticle eye drops for uveitic macular oedema

(2014) Susanne Krag et al.   ACTA OPHTHALMOLOGICA

Intravitreal Aflibercept for Diabetic Macular Edema

(2014) Jean-François Korobelnik et al.   OPHTHALMOLOGY

Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

(2014) David S. Boyer et al.   OPHTHALMOLOGY

Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration

(2014) Takashi Ueta et al.   OPHTHALMOLOGY

Ranibizumab for Diabetic Macular Edema

(2012) Quan Dong Nguyen et al.   OPHTHALMOLOGY

Topical Mecamylamine for Diabetic Macular Edema

(2010) Peter A. Campochiaro et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema

(2010) Sakiko Nakano et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY